Cohort profile: the Finnish Genetics of Pre-eclampsia Consortium (FINNPEC)

Tiina Jääskeläinen, Seppo Heinonen, Eero Kajantie, Juha Kere, Katja Kivinen, Anneli Pouta, Hannele Laivuori, FINNPEC Study Group, Tiina Jääskeläinen, Seppo Heinonen, Eero Kajantie, Juha Kere, Katja Kivinen, Anneli Pouta, Hannele Laivuori, FINNPEC Study Group

Abstract

Purpose: The Finnish Genetics of Pre-eclampsia Consortium (FINNPEC) Study was established to set up a nationwide clinical and DNA database on women with and without pre-eclampsia (PE), including their partners and infants, in order to identify genetic risk factors for PE.

Participants: FINNPEC is a cross-sectional case-control cohort collected from 5 university hospitals in Finland during 2008-2011. A total of 1450 patients with PE and 1065 pregnant control women without PE (aged 18-47 years) were recruited. Altogether, there were 1377 full triads (625 PE and 752 control triads).

Findings to date: The established cohort holds both clinical and genetic information of mother-infant-father triads representing a valuable resource for studying the pathogenesis of the disease. Furthermore, maternal biological samples (first and third trimester serum and placenta) will provide additional information for PE research. Until now, research has encompassed studies on candidate genes, Sanger and next-generation sequencing, and various studies on the placenta. FINNPEC has also participated in the InterPregGen study, which is the largest investigation on maternal and fetal genetic factors underlying PE until now.

Future plans: Ongoing studies focus on elucidating the role of immunogenetic and metabolic factors in PE. Data on morbidity and mortality will be collected from mothers and fathers through links to the nationwide health registers.

Keywords: Pre-eclampsia; Pregnancy.

Conflict of interest statement

Conflicts of Interest: None declared.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Flow chart of the FINNPEC Study. FINNPEC, Finnish Genetics of Pre-eclampsia Consortium. IUGR, intrauterine growth restriction.

References

    1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785–99. 10.1016/S0140-6736(05)17987-2
    1. Walker JJ. Pre-eclampsia. Lancet 2000;356:1260–5. 10.1016/S0140-6736(00)02800-2
    1. Steegers EA, von Dadelszen P, Duvekot JJ et al. . Pre-eclampsia. Lancet 2010;376:631–44. 10.1016/S0140-6736(10)60279-6
    1. Khan KS, Wojdyla D, Say L et al. . WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066–74. 10.1016/S0140-6736(06)68397-9
    1. Ahn H, Park J, Gilman-Sachs A et al. . Immunologic characteristics of preeclampsia, a comprehensive review. Am J Reprod Immunol 2011;65:377–94. 10.1111/j.1600-0897.2010.00913.x
    1. Levine RJ, Maynard SE, Qian C et al. . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83. 10.1056/NEJMoa031884
    1. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol 2010;63:534–43. 10.1111/j.1600-0897.2010.00831.x
    1. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011;31:33–46. 10.1016/j.semnephrol.2010.10.004
    1. Chesley LC, Annitto JE, Cosgrove RA. The familial factor in toxemia of pregnancy. Obstet Gynecol 1968;32:303–11.
    1. Arngrimsson R, Björnsson S, Geirsson RT et al. . Genetic and familial predisposition to eclampsia and pre-eclampsia in a defined population. Br J Obstet Gynaecol 1990;97:762–9. 10.1111/j.1471-0528.1990.tb02569.x
    1. Morgan L. Update on genetics of pre-eclampsia. Pregnancy Hypertens 2013;3:59–60. 10.1016/j.preghy.2013.04.009
    1. Williams PJ, Broughton Pipkin F. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011;25:405–17. 10.1016/j.bpobgyn.2011.02.007
    1. Moses EK, Lade JA, Guo G et al. . A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet 2000;67:1581–5. 10.1086/316888
    1. Laivuori H, Lahermo P, Ollikainen V et al. . Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet 2003;72:168–77. 10.1086/345311
    1. Johnson MP, Brennecke SP, East CE et al. . Genome-wide association scan identifies a risk locus for preeclampsia on 2q14, near the inhibin, beta B gene. PLoS ONE 2012;7:e33666 10.1371/journal.pone.0033666
    1. Chappell S, Morgan L. Searching for genetic clues to the causes of pre-eclampsia. Clin Sci (Lond) 2006;110:443–58. 10.1042/CS20050323
    1. Brown MC, Best KE, Pearce MS et al. . Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 2013;28:1–19. 10.1007/s10654-013-9762-6
    1. ACOG Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159–67.
    1. Pihkala J, Hakala T, Voutilainen P et al. . [Characteristic of recent fetal growth curves in Finland]. Duodecim 1989;105:1540–6.
    1. Herse F, Lamarca B, Hubel CA et al. . Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. Circulation 2012;126:2990–9. 10.1161/CIRCULATIONAHA.112.127340
    1. Kaartokallio T, Klemetti MM, Timonen A et al. . Microsatellite polymorphism in the heme oxygenase-1 promoter is associated with nonsevere and late-onset preeclampsia. Hypertension 2014;64:172–7. 10.1161/HYPERTENSIONAHA.114.03337
    1. Lokki AI, Aalto-Viljakainen T, Meri S et al. . Genetic analysis of membrane cofactor protein (CD46) of the complement system in women with and without preeclamptic pregnancies. PLoS ONE 2015;10:e0117840 10.1371/journal.pone.0117840
    1. Kaartokallio T, Cervera A, Kyllönen A et al. . Gene expression profiling of pre-eclamptic placentae by RNA sequencing. Sci Rep 2015;5:14107 10.1038/srep14107
    1. Lokki AI, Heikkinen-Eloranta J, Jarva H et al. . Complement activation and regulation in preeclamptic placenta. Front Immunol 2014;5:312 10.3389/fimmu.2014.00312
    1. Reichhardt MP, Jarva H, Lokki AI et al. . The salivary scavenger and agglutinin (SALSA) in healthy and complicated pregnancy. PLoS ONE 2016;11:e0147867 10.1371/journal.pone.0147867
    1. Johnson MP, Brennecke SP, East CE et al. . Genetic dissection of the pre-eclampsia susceptibility locus on chromosome 2q22 reveals shared novel risk factors for cardiovascular disease. Mol Hum Reprod 2013;19:423–37. 10.1093/molehr/gat011
    1. Majander KK, Villa PM, Kivinen K et al. . A follow-up linkage study of Finnish pre-eclampsia families identifies a new fetal susceptibility locus on chromosome 18. Eur J Hum Genet 2013;21:1024–6. 10.1038/ejhg.2013.6
    1. Morgan L, McGinnis R, Steinthorsdottir V et al. . InterPregGen: genetic studies of pre-eclampsia in three continents. Nor Epidemiol 2014;24:141–6.
    1. Roberts JM, Mascalzoni D, Ness RB et al. , Global Pregnancy Collaboration. Collaboration to understand complex diseases: preeclampsia and adverse pregnancy outcomes. Hypertension 2016;67:681–7. 10.1161/HYPERTENSIONAHA.115.06133
    1. Esplin MS, Fausett MB, Fraser A et al. . Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001;344:867–72. 10.1056/NEJM200103223441201
    1. Lie RT, Rasmussen S, Brunborg H et al. . Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ 1998;316:1343–7. 10.1136/bmj.316.7141.1343
    1. Kenny LC, Black MA, Poston L et al. . Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension 2014;64:644–52. 10.1161/HYPERTENSIONAHA.114.03578

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera